Shionogi & Co (TYO:4507) revised its dividend forecast for the fiscal year ending March 31, 2025, increasing the year-end dividend to 33 yen per share, up from the previous forecast of 29 yen, according to a Thursday filing on the Tokyo Stock Exchange.
The company now expects annual dividends of 184 yen per share, an increase of 24 yen from the prior year, reflecting 13 consecutive years of dividend growth.
Shionogi's strong performance, driven by the success of its treatments such as Xocova for COVID-19 and Xofluza for influenza, as well as the global expansion of its Cefiderocol sales, contributed to the revision.
The company is also advancing its growth phase, particularly with its COVID-19 treatment Ensitrelvir and HIV treatments through its ViiV Healthcare partnership.
Price (JPY): $2385.00, Change: $-35, Percent Change: -1.43%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.